Frauenheilkunde up2date 2014; 8(4): 239-250
DOI: 10.1055/s-0033-1357978
Allgemeine Gynäkologie und gynäkologische Onkologie
Georg Thieme Verlag KG Stuttgart · New York

Vulvakarzinom: primäre und adjuvante Therapie

Sven Mahner
,
Lisa Wagner
,
Fabian Trillsch
,
Donata Grimm
,
Fritz Jänicke
,
Cordula Petersen
,
Linn Wölber
Further Information

Publication History

Publication Date:
29 August 2014 (online)

Kernaussagen

Das Vulvakarzinom gehört zu den selteneren gynäkologischen Tumorerkrankungen. Da aber zunehmend jüngere Frauen erkranken, müssen neben der onkologischen Sicherheit auch psychosoziale Aspekte bei der Erstellung eines individuellen Therapiekonzepts bedacht werden. Die optimale Therapie des Vulvakarzinoms zeichnet sich durch eine individuelle und stadienadaptierte Planung aus. Die operative Radikalität sollte so gering wie möglich gehalten werden. Es wird erwartet, dass künftig multimodale Therapien bestehend aus Operation, Bestrahlung und medikamentösen Ansätzen noch weiter an Bedeutung gewinnen werden.

 
  • Literatur

  • 1 Beller U, Quinn M, Benedet J et al. Carcinoma of the vulva. FIGO 26th Annual report on the results of treatment in gynecological cancer. Int J Gynaecol Obstet 2006; 95 (Suppl. 01) S7-S27
  • 2 Judson P, Habermann E, Baxter N et al. Trends in the incidence of invasive and in situ vulvar carcinoma. Obstet Gynecol 2006; 107: 1018-1022
  • 3 Madsen B, Jensen H, van den Brule A et al. Risk factors for invasive squamous cell carcinoma of the vulva and vagina – population-based case-control study in Denmark. Int J Cancer 2008; 122: 2827-2834
  • 4 Messing M, Gallup D. Carcinoma of the vulva in young women. Obstet Gynecol 1995; 86: 51-54
  • 5 Gadducci A, Cionini L, Romanini A et al. Old and new perspectives in the management of high-risk, locally advanced or recurrent, and metastatic vulvar cancer. Crit Rev Oncol Hematol 2006; 60: 227-241
  • 6 Woelber L, Mahner S, Voelker K et al. Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer. Anticancer Res 2009; 29: 545-552
  • 7 Lin J, DuBeshter B, Angel C et al. Morbidity and recurrence with modifications of radical vulvectomy and groin dissection. Gynecol Oncol 1992; 47: 80-86
  • 8 Magrina J, Gonzalez-Bosquet J, Weaver A et al. Primary squamous cell cancer of the vulva: radical versus modified radical vulvar surgery. Gynecol Oncol 1998; 71: 116-121
  • 9 Byron S, Lamb E, Yonemoto R et al. Radical inguinal node dissection in the treatment of cancer. Surg Gynecol Obstet 1962; 114: 401-408
  • 10 Siller B, Alvarez R, Conner W et al. T2/3 vulva cancer: a case-control study of triple incision versus en bloc radical vulvectomy and inguinal lymphadenectomy. Gynecol Oncol 1995; 57: 335-339
  • 11 Ansink A, van der Velden J. Surgical interventions for early squamous cell carcinoma of the vulva. Cochrane Database Syst Rev 2000; (2) CD002036
  • 12 Heaps J, Fu Y, Montz F et al. Surgical-pathologic variables predictive of local recurrence in squamous cell carcinoma of the vulva. Gynecol Oncol 1990; 38: 309-314
  • 13 Olawaiye A, Lee L, Krasner C, Neil H. Treatment of squamous cell vulvar cancer with the anti-EGFR tyrosine kinase inhibitor Tarceva. Gynecol Oncol 2007; 106: 628-630
  • 14 Burke T, Levenback C, Coleman R et al. Surgical therapy of T1 and T2 vulvar carcinoma: further experience with radical wide excision and selective inguinal lymphadenectomy. Gynecol Oncol 1995; 97: 215-220
  • 15 Farias-Eisner R, Cirisano F, Grouse D et al. Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease. Gynecol Oncol 1994; 53: 55-58
  • 16 DiSaia P, Creasman W, Rich W. An alternate approach to early cancer of the vulva. Am J Obstet Gynecol 1979; 133: 825-832
  • 17 Hampl M, Kueppers V, Bender H. Single large inguinal lymph node metastasis in human papillomavirus-induced early invasive vulvar cancer of the anterior fourchette in two young women. Gynecol Obstet Invest 2009; 67: 42-45
  • 18 Kunos C, Simpkins F, Gibbons H et al. Radiation therapy compared with pelvic node resection for node-positive vulvar cancer: a randomized controlled trial. Obstet Gynecol 2009; 114: 537-546
  • 19 Wittekind C, Meyer H eds. TNM Klassifikation maligner Tumoren. New York: Wiley VCH; 2002
  • 20 Woelber L, Choschzick M, Eulenburg C et al. Prognostic value of pathological resection margin distance in squamous cell cancer of the vulva. Ann Surg Oncol 2011; 18: 3811-3818
  • 21 Kelley III J, Burke T, Tornos C et al. Minimally invasive vulvar carcinoma: an indication for conservative surgical therapy. Gynecol Oncol 1992; 44: 240-244
  • 22 Magrina J, Webb M, Gaffey T et al. Stage I squamous cell cancer of the vulva. Am J Obstet Gynecol 1979; 134: 453-459
  • 23 Sidor J, Diallo-Danebrock R, Eltze E et al. Challenging the concept of microinvasive carcinoma of the vulva: report of a case with regional lymph node recurrence and review of the literature. BMC Cancer 2006; 6: 157
  • 24 Homesley H, Bundy B, Sedlis A et al. Prognostic factors for groin node metastasis in squamous cell carcinoma of the vulva (a Gynecologic Oncology Group study). Gynecol Oncol 1993; 49: 279-283
  • 25 Bell J, Jayanthi S, Reid G. Complete groin lymphadenectomy with preservation of the fascia lata in the treatment of vulvar carcinoma. Gynecol Oncol 2000; 77: 314-318
  • 26 Gaarenstroom K, Kenter G, Trimbos J et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 2003; 13: 522-527
  • 27 Rouzier R, Haddad B, Plantier F et al. Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet Gynecol 2002; 100: 1159-1167
  • 28 Woelber L, Mahner S, Voelker C et al. Clinicopathological prognostic factors and patterns of recurrence in vulvar cancer. Anticancer Res 2009; 29: 545-552
  • 29 Levenback C, Burke T, Gershenson D et al. Intraoperative lymphatic mapping for vulvar cancer. Obstet Gynecol 1994; 84: 163-167
  • 30 De Cicco C, Sideri M, Bartolomei M et al. Sentinel node biopsy in early vulvar cancer. Br J Cancer 2000; 82: 295-299
  • 31 Sliutz G, Reinthaller A, Lantzsch T et al. Lymphatic mapping of sentinel nodes in early vulvar cancer. Gynecol Oncol 2002; 84: 449-452
  • 32 van der Zee A, Oonk M, Hullu J et al. Sentinel node dissection is safe in the treatment of early-stage vulvar cancer. J Clin Oncol 2008; 26: 884-889
  • 33 Hacker N, Berek J, Lagasse L et al. Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol 1983; 61: 408-412
  • 34 Rodolakis A, Diakomanolis E, Voulgaris Z et al. Squamous vulvar cancer: a clinically based individualization of treatment. Gynecol Oncol 2000; 78: 346-351
  • 35 Han S, Kim D, Higgins S et al. Chemoradiation as primary or adjuvant treatment for locally advanced carcinoma of the vulva. Int J Radiat Oncol Biol Phys 2000; 47: 1235-1244
  • 36 Andrews S, Williams B, DePriest P et al. Therapeutic implications of lymph nodal spread in lateral T1 and T2 squamous cell carcinoma of the vulva. Gynecol Oncol 1994; 55: 41-46
  • 37 Farias-Eisner R, Cirisano F, Grouse D et al. Conservative and individualized surgery for early squamous carcinoma of the vulva: the treatment of choice for stage I and II (T1-2N0-1M0) disease. Gynecol Oncol 1994; 53: 55-58
  • 38 Bundy B, Dvoretsky P, Creasman W. Early stage I carcinoma of the vulva treated with ipsilateral superficial inguinal lymphadenectomy and modified radical hemivulvectomy: a prospective study of the Gynecologic Oncology Group. Obstet Gynecol 1992; 49: 490-497
  • 39 Woelber L, Eulenburg C, Choschzick M et al. Prognostic role of lymph node metastases in vulvar cancer and implications for adjuvant treatment. Int J Gynecol Cancer 2012; 22: 503-508
  • 40 Levenback C, Morris M, Burke T et al. Groin dissection practices among gynecologic oncologists treating early vulvar cancer. Gynecol Oncol 1996; 62: 73-77
  • 41 Micheletti L, Borgno G, Barbero M et al. Deep femoral lymphadenectomy with preservation of the fascia lata. Preliminary report on 42 invasive vulvar carcinomas. J Reprod Med 1990; 35: 1130-1133
  • 42 Gaarenstroom K, Kenter G, Trimbos J et al. Postoperative complications after vulvectomy and inguinofemoral lymphadenectomy using separate groin incisions. Int J Gynecol Cancer 2003; 13: 522-527
  • 43 Rouzier R, Haddad B, Plantier F et al. Local relapse in patients treated for squamous cell vulvar carcinoma: incidence and prognostic value. Obstet Gynecol 2002; 100: 1159-1167
  • 44 Homesley H, Bundy B, Sedlis A et al. Radiation therapy versus pelvic node resection for carcinoma of the vulva with positive groin nodes. Obstet Gynecol 1986; 68: 733-740
  • 45 Mahner S, Jueckstock J, Hilpert F et al. Impact of adjuvant therapy in lymph-node positive vulvar cancer: The AGO CARE 1 study. J Clin Oncol 2012; 30 (Suppl.) abstract 5007
  • 46 Curry S, Taylor Wharton J, Felix R. Positive lymph nodes in vulvar squamous carcinoma. Gynecol Oncol 1980; 9: 63-67
  • 47 Hacker N, Berek J, Lagasse L et al. Management of regional lymph nodes and their prognostic influence in vulvar cancer. Obstet Gynecol 1983; 61: 408-412
  • 48 de Hullu J, van der Zee A. Surgery and radiotherapy in vulvar cancer. Crit Rev Oncol Hematol 2006; 60: 38-58
  • 49 Burger M, Hollema H, Emanuels A et al. The importance of the groin node status for the survival of T1 and T2 vulval carcinoma patients. Gynecol Oncol 1995; 57: 327-334
  • 50 Bellati F, Angioli R, Manci N et al. Single agent cisplatin chemotherapy in surgically resected vulvar cancer patients with multiple inguinal lymph node metastases. Gynecol Oncol 2005; 96: 227-231
  • 51 Thornton jr. W, Flanagan jr. W. Pelvic exenteration in the treatment of advanced malignancy of the vulva. Am J Obstet Gynecol 1973; 117: 774-781
  • 52 Hockel M, Dornhofer N. Vulvovaginal reconstruction for neoplastic disease. Lancet Oncol 2008; 9: 559-568
  • 53 Weikel W, Hofmann M, Steiner E et al. Reconstructive surgery following resection of primary vulvar cancers. Gynecol Oncol 2005; 99: 92-100
  • 54 Slevin N, Pointon R. Radical radiotherapy for carcinoma of the vulva. Br J Radiol 1989; 62: 145-147
  • 55 Pohar S, Hoffstetter S, Peiffert D et al. Effectiveness of brachytherapy in treating carcinoma of the vulva. Int J Radiat Oncol Biol Phys 1995; 32: 1455-1460
  • 56 Sharma D, Rath G, Kumar S et al. Treatment outcome of patients with carcinoma of vulva: experience from a tertiary cancer center of India. J Cancer Res Ther 2010; 6: 503-507
  • 57 Hoffman M. Squamous-cell carcinoma of the vulva: locally advanced disease. Best Pract Res Clin Obstet Gynaecol 2003; 17: 635-647
  • 58 Moore D, Thomas G, Montana G et al. Preoperative chemoradiation for advanced vulvar cancer: a phase II study of the Gynecologic Oncology Group. Int J Radiat Oncol Biol Phys 1998; 42: 79-85
  • 59 Moore D, Ali S, Koh W et al. A phase II trial of radiation therapy and weekly cisplatin chemotherapy for the treatment of locally-advanced squamous cell carcinoma of the vulva: a gynecologic oncology group study. Gynecol Oncol 2012; 124: 529-533
  • 60 Tans L, Ansink A, van Rooij P et al. The role of chemo-radiotherapy in the management of locally advanced carcinoma of the vulva: single institutional experience and review of literature. Am J Clin Oncol 2010; 34: 22-26
  • 61 van Doorn H, Ansink A, Verhaar-Langereis M et al. Neoadjuvant chemoradiation for advanced primary vulvar cancer. Cochrane Database Syst Rev 2006; (3) CD003752
  • 62 Cormio G, Loizzi V, Gissi F et al. Cisplatin and vinorelbine chemotherapy in recurrent vulvar carcinoma. Oncology 2009; 77: 281-284
  • 63 Wagenaar H, Colombo N, Vergote I et al. Bleomycin, methotrexate, and CCNU in locally advanced or recurrent, inoperable, squamous-cell carcinoma of the vulva: an EORTC Gynaecological Cancer Cooperative Group Study. Gynecol Oncol 2001; 81: 348-354
  • 64 Witteveen P, van der Velden J, Vergote I et al. Phase II study on paclitaxel in patients with recurrent, metastatic or locally advanced vulvar cancer not amenable to surgery or radiotherapy: a study of the EORTC-GCG (European Organisation for Research and Treatment of Cancer–Gynaecological Cancer Group). Ann Oncol 2009; 20: 1511-1516
  • 65 Monk B, Sill M, McMeekin D et al. Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a Gynecologic Oncology Group study. J Clin Oncol 2009; 27: 4649-4655
  • 66 Horowitz N, Olawaiye A, Borger D et al. Phase II trial of erlotinib in women with squamous cell carcinoma of the vulva. Gynecol Oncol 2012; 127: 141-146
  • 67 Sobin LH, Gospodarowicz M, Wittekind C. Vulva. TNM Online 2010; 197-201